Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Momenta And Mylan Make Strides On Aflibercept

Partners Are Aiming For Market Entry In 2023

Executive Summary

Having largely shelved the firms' global biosimilars collaboration that kicked off early in 2016, Momenta and Mylan are still working towards bringing a biosimilar to the Eylea blockbuster to the US, which currently has a market worth valued at more than $4.5bn.

You may also be interested in...



Samsung Bioepis Moves Eylea Biosimilar To Phase III

Biosimilar competition to Regeneron’s Eylea (aflibercept) eye-disease biologic may emerge as early as 2023, with at least three firms moving candidates to Phase III development following Samsung Bioepis’ study initiation.

Mylan Is Only Just Beginning Its Biosimilars Journey

Despite having biosimilars of insulin glargine and etanercept that are expected to launch in the US and Europe respectively midway through this year, a biosimilar bevacizumab candidate filed in both regions, an in-development Botox rival still being considered and several other biosimilars already on the market around the world, Mylan insists that its biosimilars journey is just beginning.

Momenta Shelves Adalimumab But Persists With Aflibercept

Having failed to find a commercial partner, Momenta has halted development on its adalimumab biosimilar. But it is continuing to work on biosimilar aflibercept in conjunction with partner Mylan.

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel